Mangalam Drugs & Organics Limited (NSE:MANGALAM)
India
· Delayed Price · Currency is INR 73.43
-2.85 (-3.74%)
May 6, 2025, 3:29 PM IST
Mangalam Drugs & Organics Revenue
Mangalam Drugs & Organics had revenue of 885.53M INR in the quarter ending December 31, 2024, a decrease of -8.75%. This brings the company's revenue in the last twelve months to 3.47B, down -3.54% year-over-year. In the fiscal year ending March 31, 2024, Mangalam Drugs & Organics had annual revenue of 3.67B, down -0.77%.
Revenue (ttm)
3.47B
Revenue Growth
-3.54%
P/S Ratio
0.35
Revenue / Employee
8.03M
Employees
432
Market Cap
1.22B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 3.67B | -28.42M | -0.77% |
| Mar 31, 2023 | 3.70B | -806.66M | -17.89% |
| Mar 31, 2022 | 4.51B | 708.84M | 18.65% |
| Mar 31, 2021 | 3.80B | 976.24M | 34.57% |
| Mar 31, 2020 | 2.82B | 547.74M | 24.07% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 516.03B |
| Divi's Laboratories | 90.78B |
| Cipla | 267.20B |
| Apollo Hospitals Enterprise | 211.46B |
| Mankind Pharma | 116.41B |
| Zydus Lifesciences | 222.47B |
| Aurobindo Pharma | 309.22B |
| Alkem Laboratories | 127.57B |